Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion type Assertion NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_head.
- NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion description "[Placebo-blinded administration of the humanized anti-human E- and P-selectin monoclonal antibody (HuEP5C7, 20 mg/kg IV, n=9; placebo, n=9) immediately after the onset of 1 hour of temporary ischemia resulted in trends showing reduced polymorphonuclear leukocyte (PMN) infiltration into ischemic cortex, reduced infarct volumes (by 41%), improved neurological score (by 35%), and improved ability to self-care (by 39%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_provenance.
- NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion evidence source_evidence_literature NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_provenance.
- NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion SIO_000772 12433835 NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_provenance.
- NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion wasDerivedFrom befree-20150227 NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_provenance.
- NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_assertion wasGeneratedBy ECO_0000203 NP690054.RAXLQR_Inv5-yBoFAEQdNp_tMRmriAeFuCj3y5jzC-XYI130_provenance.